166 related articles for article (PubMed ID: 32422144)
1. Perforin and resistance to SARS coronavirus 2.
Cunningham L; Simmonds P; Kimber I; Basketter DA; McFadden JP
J Allergy Clin Immunol; 2020 Jul; 146(1):52-53. PubMed ID: 32422144
[No Abstract] [Full Text] [Related]
2. COVID-19 pneumonia: CD8
Jiang Y; Wei X; Guan J; Qin S; Wang Z; Lu H; Qian J; Wu L; Chen Y; Chen Y; Lin X
Clin Immunol; 2020 Sep; 218():108516. PubMed ID: 32574709
[TBL] [Abstract][Full Text] [Related]
3. Defining the CD39/CD73 Axis in SARS-CoV-2 Infection: The CD73
Ahmadi P; Hartjen P; Kohsar M; Kummer S; Schmiedel S; Bockmann JH; Fathi A; Huber S; Haag F; Schulze Zur Wiesch J
Cells; 2020 Jul; 9(8):. PubMed ID: 32707842
[TBL] [Abstract][Full Text] [Related]
4. Lymphopenia in COVID-19: Therapeutic opportunities.
Fathi N; Rezaei N
Cell Biol Int; 2020 Sep; 44(9):1792-1797. PubMed ID: 32458561
[TBL] [Abstract][Full Text] [Related]
5. Secondary hemophagocytic lymphohistiocytosis, HScore and COVID-19.
Loscocco GG
Int J Hematol; 2020 Jul; 112(1):125-126. PubMed ID: 32474804
[No Abstract] [Full Text] [Related]
6. Immunologic Features in Coronavirus Disease 2019: Functional Exhaustion of T Cells and Cytokine Storm.
Mahmoudi S; Rezaei M; Mansouri N; Marjani M; Mansouri D
J Clin Immunol; 2020 Oct; 40(7):974-976. PubMed ID: 32648027
[No Abstract] [Full Text] [Related]
7. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
Wei J; Zhao J; Han M; Meng F; Zhou J
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
[TBL] [Abstract][Full Text] [Related]
8. Storm, typhoon, cyclone or hurricane in patients with COVID-19? Beware of the same storm that has a different origin.
Alunno A; Carubbi F; Rodríguez-Carrio J
RMD Open; 2020 May; 6(1):. PubMed ID: 32423970
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 cytokine storm: the interplay between inflammation and coagulation.
Jose RJ; Manuel A
Lancet Respir Med; 2020 Jun; 8(6):e46-e47. PubMed ID: 32353251
[No Abstract] [Full Text] [Related]
10. More bricks in the wall against SARS-CoV-2 infection: involvement of γ9δ2 T cells.
Rijkers G; Vervenne T; van der Pol P
Cell Mol Immunol; 2020 Jul; 17(7):771-772. PubMed ID: 32467616
[No Abstract] [Full Text] [Related]
11. Natural Killer Cell Dysfunction and Its Role in COVID-19.
van Eeden C; Khan L; Osman MS; Cohen Tervaert JW
Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32883007
[TBL] [Abstract][Full Text] [Related]
12. Convalescent donor SARS-COV-2-specific cytotoxic T lymphocyte infusion as a possible treatment option for COVID-19 patients with severe disease has not received enough attention till date.
Hanley B; Roufosse CA; Osborn M; Naresh KN
Br J Haematol; 2020 Jun; 189(6):1062-1063. PubMed ID: 32369628
[No Abstract] [Full Text] [Related]
13. COVID-19, Mast Cells, Cytokine Storm, Psychological Stress, and Neuroinflammation.
Kempuraj D; Selvakumar GP; Ahmed ME; Raikwar SP; Thangavel R; Khan A; Zaheer SA; Iyer SS; Burton C; James D; Zaheer A
Neuroscientist; 2020; 26(5-6):402-414. PubMed ID: 32684080
[TBL] [Abstract][Full Text] [Related]
14. Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection.
Lin Q; Zhu L; Ni Z; Meng H; You L
J Microbiol Immunol Infect; 2020 Oct; 53(5):821-822. PubMed ID: 32249185
[No Abstract] [Full Text] [Related]
15. Possible role of low-dose etoposide therapy for hemophagocytic lymphohistiocytosis by COVID-19.
Takami A
Int J Hematol; 2020 Jul; 112(1):122-124. PubMed ID: 32399895
[No Abstract] [Full Text] [Related]
16. The Potential Effect of Novel Coronavirus SARS-CoV-2 on NK Cells; A Perspective on Potential Therapeutic Interventions.
Jewett A
Front Immunol; 2020; 11():1692. PubMed ID: 32754162
[TBL] [Abstract][Full Text] [Related]
17. Long-term infection of SARS-CoV-2 changed the body's immune status.
Lin L; Luo S; Qin R; Yang M; Wang X; Yang Q; Zhang Y; Wang Q; Zhu R; Fan H; Wang H; Hu Y; Wang L; Hu D
Clin Immunol; 2020 Sep; 218():108524. PubMed ID: 32659373
[TBL] [Abstract][Full Text] [Related]
18. Identification of druggable inhibitory immune checkpoints on Natural Killer cells in COVID-19.
Demaria O; Carvelli J; Batista L; Thibult ML; Morel A; André P; Morel Y; Vély F; Vivier E
Cell Mol Immunol; 2020 Sep; 17(9):995-997. PubMed ID: 32612152
[No Abstract] [Full Text] [Related]
19. Cell-Free Therapies: Novel Approaches for COVID-19.
Maron-Gutierrez T; Rocco PRM
Front Immunol; 2020; 11():583017. PubMed ID: 33072130
[No Abstract] [Full Text] [Related]
20. Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection.
Cunningham L; Kimber I; Basketter DA; McFadden JP
Autoimmun Rev; 2020 Jul; 19(7):102563. PubMed ID: 32380318
[No Abstract] [Full Text] [Related]
[Next] [New Search]
